Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.050
Sell
RSI(14)
33.815
Neutral
STOCH(KDJ)(9,3,3)
9.357
Oversold
ATR(14)
0.093
High Vlolatility
CCI(14)
-110.294
Sell
Williams %R
94.286
Oversold
TRIX(12,20)
-0.505
Sell
StochRSI(14)
21.034
Buy
Dare Bioscience Inc
DARE1.690USD
+0.010+0.60%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
23.54MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Dare Bioscience Inc
Currency: USD Updated: 2026-02-06Key Insights
Dare Bioscience Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 105 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.75.In the medium term, the stock price is expected to remain stable.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Dare Bioscience Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Dare Bioscience Inc Highlights
StrengthsRisks
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.78K.
Overvalued
The company’s latest PE is -0.93, at a high 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 523.05K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.66.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
10.750
Target Price
+539.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Dare Bioscience Inc is 5.65, ranking 154 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 2.26K, representing a year-over-year decrease of 94.57%, while its net profit experienced a year-over-year decrease of 24.24%.
Score
Financials
6.77
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.61
Operational Efficiency
2.83
Growth Potential
4.94
Shareholder Returns
7.07
Dare Bioscience Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Dare Bioscience Inc is 7.74, ranking 50 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.93, which is -165.61% below the recent high of 0.61 and -1964.71% above the recent low of -19.13.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 105/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Dare Bioscience Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 11.50, with a high of 12.00 and a low of 8.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
10.750
Target Price
+507.34%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Dare Bioscience Inc
DARE
4
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Dare Bioscience Inc is 5.78, ranking 136 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.95 and the support level at 1.55, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.732
Sell
MA10
1.816
Sell
MA20
1.887
Sell
MA50
1.958
Sell
MA100
1.983
Sell
MA200
2.283
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Dare Bioscience Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 6.94%, representing a quarter-over-quarter decrease of 38.90%. The largest institutional shareholder is The Vanguard, holding a total of 523.05K shares, representing 3.66% of shares outstanding, with 1.33% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Law Custodial Inc
AMH Equity, Ltd.
Geode Capital Management, L.L.C.
Johnson (Sabrina Martucci)
Susquehanna International Group, LLP
Walters-Hoffert (Lisa)
State Street Investment Management (US)
UBS Financial Services, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Dare Bioscience Inc is 2.93, ranking 113 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.95. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.95
VaR
+6.59%
240-Day Maximum Drawdown
+50.00%
240-Day Volatility
+143.05%
Return
Best Daily Return
60 days
+18.18%
120 days
+18.18%
5 years
+25.70%
Worst Daily Return
60 days
-9.24%
120 days
-9.24%
5 years
-41.70%
Sharpe Ratio
60 days
-0.11
120 days
-0.56
5 years
-0.33
Risk Assessment
Maximum Drawdown
240 days
+50.00%
3 years
+87.19%
5 years
+93.62%
Return-to-Drawdown Ratio
240 days
-0.92
3 years
-0.33
5 years
-0.19
Skewness
240 days
+1.39
3 years
-0.22
5 years
+0.07
Volatility
Realised Volatility
240 days
+143.05%
5 years
+99.98%
Standardised True Range
240 days
+8.18%
5 years
+34.83%
Downside Risk-Adjusted Return
120 days
-97.26%
240 days
-97.26%
Maximum Daily Upside Volatility
60 days
+58.96%
Maximum Daily Downside Volatility
60 days
+45.87%
Liquidity
Average Turnover Rate
60 days
+29.72%
120 days
+15.09%
5 years
--
Turnover Deviation
20 days
-66.48%
60 days
+300.81%
120 days
+103.47%
Peer Comparison
Pharmaceuticals
Dare Bioscience Inc
DARE
5.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
